There are 2949 resources available
799TiP - PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations
Presenter: Diederik Somford
Session: E-Poster Display
Resources:
Abstract
800TiP - Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy
Presenter: Francesca Vignani
Session: E-Poster Display
Resources:
Abstract
801TiP - A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE)
Presenter: Matthew Milowsky
Session: E-Poster Display
Resources:
Abstract
802TiP - Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study
Presenter: Matteo Brunelli
Session: E-Poster Display
Resources:
Abstract
803TiP - Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients
Presenter: Miguel Angel Climent Duran
Session: E-Poster Display
Resources:
Abstract
817P - Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial
Presenter: Adriaan Vanderstichele
Session: E-Poster Display
Resources:
Abstract
804TiP - CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
Presenter: Laurence Albiges
Session: E-Poster Display
Resources:
Abstract
818P - Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study
Presenter: Aikou Okamoto
Session: E-Poster Display
Resources:
Abstract
819P - Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Presenter: Giorgio Valabrega
Session: E-Poster Display
Resources:
Abstract
820P - Phase II study of pamiparib in Chinese patients (pts) with advanced ovarian cancer (aOC)
Presenter: Xiaohua Wu
Session: E-Poster Display
Resources:
Abstract